Cardiac hypertrophy in polycythemia vera:A case report and review of literature  

作　　者：Bai-Sheng Ma Shu-Hui Zhai Wei-Wei Chen Qi-Ni Zhao 

机构地区：[1]Department of Cardiology,China-Japan Union Hospital of Jilin University,Changchun 130031,Jilin Province,China [2]Department of Cardiology,Jilin Provincial Cardiovascular Research Institute,Changchun 130031,Jilin Province,China [3]Department of Cardiology,Jilin Provincial Engineering Laboratory for Endothelial Function and Genetic Diagnosis of Cardiovascular Disease,Changchun 130031,Jilin Province,China

出　　处：《World Journal of Cardiology》2024年第11期651-659,共9页世界心脏病学杂志（英文）

基　　金：Supported by Jilin Province Health Research Talent Special Project,No.2020SCZ27.

摘　　要：BACKGROUND The combination of polycythemia vera(PV)with pathological cardiac hypertro-phy is uncommon.In this study,we describe a case of PV accompanied by pa-thological cardiac hypertrophy.It is hypothesized that the pronounced cardiac hypertrophy in this patient has a strong connection with PV.CASE SUMMARY In 2021,a 34-year-old Chinese man experienced chest constriction,shortness of breath,and palpitations during vigorous activity.Each episode lasted several minutes and resolved spontaneously following cessation of vigorous activity.He occasionally experienced syncope and vertigo without a headache.He underwent cardiac magnetic resonance imaging and was diagnosed with“hypertrophic cardiomyopathy(HCM)”.He was discharged after receiving symptomatic treat-ment,which resulted in an improvement.He presented to our department with chest constriction,shortness of breath,and respiratory distress for one month while climbing to the second floor in 2023.His blood pressure was 180/100 mmHg at the time of admittance,and he was receiving antihypertensive treat-ment.He had a history of PV for 2 years without treatment.Symptomatic treat-ment was implemented concurrently with the administration of hydroxyurea upon admission.Good blood pressure control was observed during the long-term follow-up,and echocardiography did not reveal any progression of myocardial hypertrophy.CONCLUSION Clinicians managing PV patients should remain highly vigilant regarding the risks of thrombosis and cardio-vascular complications,particularly in those with refractory hypertension.

关 键 词：Polycythemia vera Cardiomyopathy hypertrophic HYPERTENSION THROMBOSIS Case report 

分 类 号：R542.2[医药卫生—心血管疾病]